pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Darzalex
drug · antibody
save

daratumumab

pre_registrationupdated 6mo ago
by $JNJ JOHNSON & JOHNSON🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 8
  • drugdaratumumab + Gene Therapy63 co-mentions · 18 sources
  • drugDARZALEX FASPRO60 co-mentions · 15 sources
  • tagApproval60 co-mentions · 15 sources
  • drug(daratumumab + hyaluronidase (human recombinant))31 co-mentions · 16 sources
  • companyJanssen Biotech Inc30 co-mentions · 15 sources
  • tagOncology3 co-mentions · 2 sources
  • tagImmunology2 co-mentions · 1 sources
  • tagHematology2 co-mentions · 1 sources

Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for multiple myeloma and neoplasm and 37 investigational indications.

targets

ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1

all catalysts(0)

nothing on the calendar yet

Trials studying daratumumab

  • phase2Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALLrecruitingn=20
  • phase3Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myelomaactive not recruitingn=494
  • phase3A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131not yet recruitingn=300
  • phase3A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)active not recruitingn=260
  • phase1A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatmentsrecruitingn=317
  • phase3A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Plannedrecruitingn=1,000
  • phase3A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapycompletedn=395
  • phase1A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myelomaactive not recruitingn=140

News(10)

  • At ASH, drugmakers to showcase early data for three-pronged cancer therapies
    J&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment for multiple myeloma.
    biopharma_dive · 11d ago
  • Genmab soars to record highs after cancer drug succeeds in key trial
    The drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become a new treatment standard for a form of head and neck cancer.
    biopharma_dive · 18d ago
  • Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
    Analysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.
    biospace · 19d ago
  • Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
    Analysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.
    biospace · 19d ago
  • Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trial
    Extending both progression-free and overall survival, Genmab’s Rina-S “sets a high bar for future competition” in a market served by AbbVie, analysts said.
    biospace · 21d ago
  • Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosion
    Bracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession.
    biospace · 28d ago
  • J&J’s innovative medicines carried Q3 as medtech disappoints, but newer medicines absent
    While innovative medicine supported Johnson & Johnson’s “in line” earnings for the third quarter of 2026, investors were disappointed to see older medicines carrying the bag.
    biospace · 1mo ago
  • Pharma’s $500B patent problem will come in waves — not as a cliff
    Merck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.
    biopharma_dive · 1mo ago
  • Merck barred from making subcutaneous Keytruda in 8 European countries
    With the patent court siding with Halozyme, Merck faces restrictions on a product that won approval in Europe last year.
    biospace · 1mo ago
  • Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
    The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.
    biopharma_dive · 3mo ago
view all news mentions →
brand
Darzalex
trade names
Daratumumab component of darzalex faspro, Darzalex
generic
daratumumab
MOA
Lymphocyte differentiation antigen CD38 inhibitor
indication
Multiple Myeloma (Kahler Disease)
phase
pre_registration
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 4h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?